Launch of Phase 3 clinical trial with Nefecon in Japan
Launch of Phase 3 clinical trial with Nefecon in Japan |
[04-July-2024] |
STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX)("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN). The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country. *Japan Intractable Disease Information Center CONTACT: The information was sent for publication, through the agency of the contact persons set out above, on July 4, 2024 at 08:30 a.m. CET. This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Calliditas Therapeutics | ||||
Company Codes: NASDAQ-NMS:CALT, Bloomberg:CALTX@SS, ISIN:SE0010441584, RICS:CALTX.ST, Stockholm:CALTX |